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Abstract 
Review on BCL2L14, with data on DNA/RNA, on 
the protein encoded and where the gene is 
implicated. 
Identity 
Other names: BCLG 
HGNC (Hugo): BCL2L14 
Location: 12p13.2 
Local order: Flanked by ETV6 and 
LOC100506248 (prothymosin alpha-like). 
Note 
BCL2L14 encodes members of the Bcl-2 family. 
Proteins in the family contain at least one Bcl-2 
homology (BH) domain (of which there are four in 
total; termed BH1-4) and regulate cell life/death 
decisions at the level of the mitochondrion 
(intrinsic apoptotic pathway). Family members can 
be broadly divided into anti-apoptotic and pro-
apoptotic regulators; the former class includes Bcl-
2, Mcl-1 and Bcl-xL, which contain all four BH 
domains, whereas the latter class can be subdivided 
into: i. effector molecules, such as the multidomain 
(BH1-3) Bax and Bak molecules, and ii. upstream 
sentinel BH3-only proteins (e.g. Bim, Bid, Puma 
and Noxa). Bcl-2 family members undergo 
complex protein-protein interactions with each 
other. Crucially, it is the balance between pro- and 
anti-apoptotic Bcl-2 family members which 
determines if activation of the mitochondrial 
(intrinsic) apoptotic pathway occurs and, 
ultimately, whether the cell lives or dies.  
Human BCL2L14 was first characterized in 2001 
(Guo et al., 2001). Two full-length transcripts, 
encoding long and short protein isoforms (termed  
Bcl-GL and Bcl-GS), were isolated. Bcl-GS is a 
BH3-only protein, whereas Bcl-GL unusually 
contains only BH2 and BH3 domains (Guo et al., 
2001); a similar Bcl-2 family member, termed Bfk, 
has subsequently been identified (Coultas et al., 
2003). The two Bcl-G isoforms exhibit pro-
apoptotic activity, but Bcl-GL is less potent than 
Bcl-GS, attributed to negative regulation by the 
BH2 domain (Guo et al., 2001). Differences are 
also apparent between Bcl-GS and Bcl-GL in their 
patterns of tissue expression (restricted to testes 
versus ubiquitous), subcellular distribution 
(cytosolic organelles versus diffuse) and interaction 
with other Bcl-2 family members (Bcl-GS only 
shows interaction) (Guo et al., 2001). Pig and 
mouse BCL2L14 encode only one BclG protein 
isoform (termed pBcl-G and mBcl-G, respectively), 
which contains BH2 and BH3 domains, similar to 
Bcl-GL (Giam et al., 2012a; Jiang et al., 2012). 
Phylogenetic analysis of Bcl-G protein sequences 
from 14 different species has revealed the presence 
of three different clades comprising human/apes, 
rodents and pigs/cattle, raising the possibility of 
species differences in Bcl-G action (Jiang et al., 
2012). 
The BCL2L14 promoter contains a cAMP 
responsive element, an interferon-γ-activated site 
(GAS) and an interferon regulatory factor element 
(IRF-E); interferon-α and γ co-operatively 
hyperactivate BCL2L14 expression in hepatoma 
cells (Zhang et al., 2006). A consensus site for 
certain proline- and acid rich basic region leucine 
zipper proteins is also present; binding of 
thyrotroph embryonic factor (TEF) or albumin D-
site-binding protein (DBP) enhances promoter 
activity, whereas binding of nuclear factor, 
interleukin-3 regulated (NFIL3) is repressive 
(Benito et al., 2006).  
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Figure 1. Alternative splicing of BCL2L14 yields at least three transcript variants. Note that exons only are drawn to scale 
and that only those transcript variants for which reference sequences exist are shown. Transcript variants 1 and 4 differ only in 
their 5'-UTR sequence and produce an identical protein isoform (Bcl-GL), whereas the coding sequence of transcript variant 2 is 
shorter and gives rise to a protein isoform (Bcl-GS) with a distinct C-terminus. 
 
BCL2L14 has also been identified as a p53 target 
gene; the putative binding site is located within the 
first intron (Miled et al., 2005). BCL2L14 
expression is regulated in a reciprocal manner by 
protein kinase C (PKC) isozyme signalling; its 
expression is repressed by PKCε but enhanced by 
PKCδ (Caino et al., 2011). Along with other 
apoptotic regulatory genes and the putative tumour 
suppressor gene, WISP3, BCL2L14 has been 
identified as a target for oncogenic miR-221 
(Vandenboom et al., 2008). 
Several different post-translational modifications, 
which impact upon protein function, have been 
reported for Bcl-G isoforms. Bcl-GL is a target for 
phosphorylation, catalysed by the candidate 
oncoprotein maternal embryonic leucine zipper 
kinase (MELK), which is overexpressed in breast 
cancer and a range of other solid tumors (Lin et al., 
2007). The N-terminal region (amino acids 12 - 71) 
of Bcl-GL (conserved in Bcl-GS) is required for this 
interaction, and its phosphorylation inhibits 
apoptotic activity (Lin et al., 2007). Furthermore, in 
mouse cells, mBclG is a target for modification by 
a ubiquitin-like protein, termed FUBI, which in 
humans is encoded by the putative tumour 
suppressor gene FAU (Nakamura and Tanigawa, 
2003; Nakamura and Yamaguchi, 2006). The N-
terminal region of mBclG appears to be cleaved 
from the adduct. In mouse macrophages the 
FUBI/mBclG complex associates with ERKs and 
inhibits their activation by MEK1; recent work has 
further demonstrated that the adduct enhances 
lipopolysaccharide/interferon γ - induced apoptosis 
(Watanabe et al., 2013). Indeed, in human cells, 
ectopic expression of FAU promotes apoptosis, and 
both Fau and BclGL are thought to act in the same 
pathway, with the pro-apoptotic activity of Fau 
being mediated via BclGL (Pickard et al., 2009; 
Pickard et al., 2010; Pickard et al., 2011). Finally, 
interactions between Bcl-GS and JAB1 (c-Jun 
activation domain binding protein-1; aka the fifth 
subunit of the COP9 signalosome or CSN5) have 
also been reported (Liu et al., 2008). The N-
terminal region (amino acids 1 - 67) of Bcl-GS is 
required for this interaction, and these two genes 
co-operatively induce apoptosis in HeLa cells; 
JAB1 inhibits Bcl-2/Bcl-XL binding by the BH3 
domain of Bcl-GS and knock-down studies indicate 
that JAB1 is essential for Bcl-GS to induce 
apoptosis (Liu et al., 2008).  
BCL2L14 lies within 12p12, which is frequently 
deleted in lymphoid/myeloid malignancies and 
solid tumours, suggestive of the presence of tumour 
suppressor gene(s) in this locus (Montpetit et al., 
2002).  
In the case of pre-B acute lymphoblastic leukemia, 
ETV6 (rather than BCL2L14) is the target of 
deletions (Montpetit et al., 2004). In advanced 
prostate cancer however, the minimal deleted 
region is more distal to the telomere and extends 
into 12p13 (Kibel et al., 2004); expression mapping 
has demonstrated reduced BCL2L14 expression 
(Kibel et al., 2004).  
BCL2L14 expression is also dysregulated in breast 
cancer (Pickard et al., 2009), ovarian cancer 
(Heinzelmann-Schwarz et al., 2006) and in tongue 
squamous cell carcinoma (Zhang et al., 2013). 
Mutations in the BH3 domain are not however 
common occurences in cancer (Soung et al., 2006; 
Yoo et al., 2007). 
BCL2L14 expression is markedly up-regulated in 
CD4+ T-cells from patients with the autoimmune 
disorder, systemic lupus erythematosus (SLE) and 
several lines of evidence implicate this 
dysregulation in pathogenesis (Luo et al., 2009). 
Dysregulated expression of BCL2L14 in 
mammalian cells has also been noted in response to 
infection with a variety of pathogens (Flori et al., 
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2008; Mehra et al., 2010; Balas et al., 2011; Singh 
et al., 2011; Taubert et al., 2010; Almeida et al., 
2012; Wang et al., 2012), indicative of a role in 
innate immunity. 
DNA/RNA 
Description 
The gene is located on chromosome 12 on the plus 
strand at 12202778 bp from pter to 12364018 from 
pter (size is 161241 bases). It was originally 
thought to comprise 6 exons (Guo et al., 2001) but 
7 possible additional exons have subsequently been 
identified (Montpetit et al., 2002). 
Transcription 
The gene encodes multiple transcripts; reference 
sequences exist for 3 transcript variants. These give 
rise to two different protein isoforms (Fig. 1). 
Transcript variants 1 and 4 differ only in their 5'-
UTR and both encode the same protein, termed 
isoform 1 or Bcl-GL. Usage of a different splice 
acceptor site results in the production of transcript 
variant 2. This contains extra nucleotides within the 
coding sequence, resulting in a frameshift and 
consequently a truncated protein product with 
distinct C-terminal amino acids, termed isoform 2 
or Bcl-GS. Transcript variant 2 may be a candidate 
for nonsense-mediated mRNA decay (NMD), but 
the RefSeq record (NM_030766.1) has been 
retained, since there is evidence for the expression 
of protein product. However, the RefSeq 
(NM_138724.1) for a further variant, originally 
termed variant 3, which encodes Bcl-G-Median 
(Bcl-GM) (Montpetit et al., 2002), has been 
permanently suppressed, as this transcript is also a 
candidate for NMD and evidence for protein 
expression is lacking. 
Pseudogene 
There are no known pseudogenes. 
Protein 
Description 
The two protein isoforms are members of the Bcl-2 
family. Bcl-GL comprises 327 amino acids and 
contains BH2 and BH3 domains, whereas Bcl-GS 
comprises 252 amino acids and contains the BH3 
domain only (Fig. 2). The two proteins are identical 
in sequence for the first 226 amino acids. 
Expression 
Highest levels of gene expression in the adult 
human are found in testis, hence the name Bcl-G, 
for Bcl-Gonad. Indeed Bcl-GS is uniquely  
expressed in this tissue (as also noted for Bcl-GM) 
(Guo et al., 2001; Montpetit et al., 2002). Bcl-GL is 
predominantly expressed in testis, with transcripts 
also present in lung, pancreas, prostate, bone 
marrow and colon (Guo et al., 2001; Montpetit et 
al., 2002). The expression of Bcl-GL has also been 
reported in freshly isolated human T-lymphocytes 
(CD4+ and CD8+ cells) and B-lymphocytes (Luo et 
al., 2009). Both Bcl-GL and Bcl-GS transcripts are 
expressed in a wide range of breast cancer cell lines 
and cultured mammary epithelial cells, but protein 
expression has been demonstrated for the former 
isoform only (Benito et al., 2006; Lin et al., 2007). 
Bcl-G transcript expression is more variable across 
prostate cell lines (Pickard et al., 2010). High levels 
of Bcl-GS transcripts are found in testicular 
embryonal cancer cell lines, with lower levels 
present in urinary bladder and mantle cell 
lymphoma cell lines, followed by myeloid and 
breast cancer cell lines, but protein was detected for 
the testicular embryonal cancer cell lines only 
(Benito et al., 2006). 
Localisation 
Expression of GFP-tagged proteins in COS-7 cells 
has revealed a diffuse localization throughout the 
cell for Bcl-GL (similar to GFP alone), but a more 
punctate cytosolic localization, with partial co-
localization to mitochondria, for Bcl-GS (Guo et al., 
2001). The latter has been confirmed using Myc-
tagged Bcl-GS (Liu et al., 2008). Deletion of the 
BH3 domain from Bcl-GS has no effect on its 
subcellular distribution, despite preventing 
interaction with Bcl-XL (Guo et al., 2001). However 
interaction with JAB1 results in a more diffuse 
cytoplasmic localisation for Bcl-GS (Liu et al., 
2008). 
Function 
The original paper on BCL2L14 reported that GFP- 
or FLAG-tagged Bcl-GL and Bcl-GS have pro-
apoptotic activity in a range of cell lines (COS-7, 
HEK293T and PC3), and that the latter is the more 
potent isoform (Guo et al., 2001). Deletion of the 
BH2 domain from Bcl-GL allowed its interaction 
with Bcl-XL and enhanced apoptotic activity, 
whereas the BH3 domain of Bcl-GS was required 
for interaction with Bcl-XL and apoptotic activity 
(Guo et al., 2001). 
The pro-apoptotic activity of Bcl-GL in COS-7 cells 
has been independently confirmed, and it has been 
further demonstrated that this activity is negatively 
regulated by phosphorylation, catalyzed by MELK 
(Lin et al., 2007). Similarly, Bcl-GS has been 
reported to induce basal apoptosis in HeLa cells; an 
effect that is potentiated by JAB1 (Liu et al., 2008). 
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Figure 2. Protein isoforms encoded by BCL2L14. Homologous sequence between the two isoforms is depicted by the same 
colour pattern. Note that BclGL contains BH2 and BH3 domains whereas BclGS is a BH3-only protein. Potential sites of post-
translational modification/interaction with non-Bcl-2 family members are also indicated. 
 
The latter is thought to out-compete Bcl-2/Bcl-XL 
for binding of Bcl-GS (Liu et al., 2008). On the 
other hand, transfection of Huh-7 cells with Bcl-GL 
has no effect on basal apoptosis (Zhang et al., 
2006), while the survival of HCT116 and NTERA2 
cells is unaffected by elevated levels of Bcl-GS 
consequent upon ectopic TEF expression (Benito et 
al., 2006), suggesting that cell context is important 
for the apoptotic activity of Bcl-G protein isoforms. 
Crucially lentiviral transfection of Bcl-GL results in 
enhanced apoptosis of CD4+ T-cells from healthy 
subjects, demonstrating that pro-apoptotic activity 
is not restricted to transformed cells (Luo et al., 
2009). 
Furthermore, siRNA-mediated silencing of 
BCL2L14 gene expression attenuates apoptosis 
induction in several cell lines in response to diverse 
stimuli, including: ultraviolet-C irradiation (22Rv1 
and HEK293T cells) (Pickard et al., 2010; Pickard 
et al., 2011), etoposide (HCT116 cells) (Benito et 
al., 2006), neratinib (SKBR-3 cells) (Seyhan et al., 
2012), p53-induction (Saos-2 cells) (Miled et al., 
2005), and ectopic expression of the putative 
tumour suppressor gene FAU (HEK293T cells) 
(Pickard et al., 2011). BCL2L14 is itself a target 
gene for the apoptosis master regulator p53 (Miled 
et al., 2005), and it is one of a subset of pro-
apoptotic genes whose expression is hyperactivated 
in response to interferon-α and -γ co-treatment of 
hepatoma cells (Zhang et al., 2006). Its expression 
is also increased in mammalian cells following 
exposure to a diverse range of apoptotic stimuli 
(including chemotherapeutic agents) such as: 
gamma- radiation therapy (Finnberg et al., 2008), 
UV-C irradiation (Pickard et al., 2011), arsenic 
trioxide (Galimberti et al., 2012), nanoparticulate 
tetraiodothyroacetic acid (Glinskii et al., 2009), 
etoposide and cisplatin (Benito et al., 2006). 
Mutations in pancreatic/duodenum homeobox 
protein 1 (PDX1) can result in human type 2 
diabetes. Haploinsufficiency of this gene in mice 
also causes diabetes and is associated with 
enhanced apoptosis/necrosis of β-cells. In this 
regard, BCL2L14 has been identified as one of 
several genes encoding pro-apoptotic Bcl-2 family 
members whose expression is markedly up-
regulated following shRNA-mediated depletion of 
Pdx1 in mouse insulinoma MIN6 cells (Fujimoto et 
al., 2010). Additionally BCL2L14 is one of several 
pro-apoptotic genes that is up-regulated upon 
exposure of human fibroblasts to pressure-induced 
oxidative stress (Oh et al., 2008). 
The recent production of a mouse in which 
BCL2L14 is inactivated has demonstrated no 
apparent deleterious effects on cell types that 
normally express this gene (Giam et al., 2012b), 
perhaps suggesting some degree of functional 
redundancy. These authors further demonstrated 
that mBclG had negligible pro-apoptotic activity in 
human 293T cells and that the BH3 domain was 
incapable of binding Bcl-2 family members. Rather 
mBclG was capable of binding several novel 
partners, including transport particle protein 
(TRAPP) complex proteins, suggesting a potential 
role for mBclG in vesicle trafficking (Giam et al., 
2012b). As regards pig Bcl-G, its ectopic 
expression in a porcine kidney cell line stimulates 
apoptosis induced by polyinosinic: polycytidylic 
acid (synthetic analogue of dsRNA and mimic of 
viral infection) (Jiang et al., 2012). 
Homology 
Homologues of BCL2L14 have been identified in a 
wide range of species (e.g. see Jiang et al., 2012). 
However, the Bcl-GS protein isoform is specific to 
humans (Giam et al., 2012a). Mouse and pig Bcl-G 
share 68% and 71% amino acid identity, 
respectively, with human Bcl-GL. 
Implicated in 
Prostate cancer 
Note 
In advanced prostate cancer, deletion of 12p12 is 
frequently seen. Expression mapping of genes 
within/adjacent to the minimal deleted region in 
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clinical tumours has demonstrated reduced 
expression of BCL2L14 and two other genes 
(DUSP16 and FLJ10298) (Kibel et al., 2004); 
reduced expression of BCL2L14 has been 
independently confirmed (Pickard et al., 2010). In 
the latter study, transcript levels were highly 
correlated with those of FAU, which also regulates 
apoptosis and which may act via the post-
translational modification of Bcl-G (Pickard et al., 
2010). Notably, down-regulation of BCL2L14 gene 
expression in the prostate cancer 22Rv1 cell line 
protects cells from apoptosis induction by 
ultraviolet-C irradiation (Pickard et al., 2010). 
BCL2L14 has been identified as a member of a four 
gene signature that accurately predicts prostate 
cancer recurrence, but high expression of BCL2L14 
is associated with tumour recurrence (Latil et al., 
2003). 
Breast cancer 
Note 
Single nucleotide polymorphisms of high frequency 
loss of heterozygosity that affect BCL2L14 are 
found more commonly in infiltrating ductal 
carcinoma than in infiltrating lobular carcinoma of 
the breast (Loo et al., 2008). In breast ductal 
carcinoma, BCL2L14 expression is reduced, and 
silencing of BCL2L14 expression in the T-47D 
breast cancer cell line attenuates apoptosis 
induction by exogenous stimuli (Pickard et al., 
2009). A genome-wide RNAi screen has recently 
shown that BCL2L14 silencing in SKBR-3 results 
in resistance to the novel pan-ErbB inhibitor, 
neratinib (Seyhan et al., 2012). BCL2L14 has also 
been implicated in the anti-survival effects of 
nanoparticulate tetraiodothyroacetic acid on MDA-
MB-231 cells (Glinskii et al., 2009).  
As regards genes involved in the post-translational 
modification of Bcl-G, FAU expression is down-
regulated and MELK expression is up-regulated in 
breast tumour tissue (Pickard et al., 2009). These 
latter changes were associated with poor patient 
prognosis, but no relationship was apparent 
between BCL2L14 gene expression and patient 
survival (Pickard et al., 2009), suggesting that the 
regulation of Bcl-G activity by post-translational 
modification is more important than the level of 
BCL2L14 expression per se in determining patient 
survival. 
Ovarian cancer 
Note 
Elevated levels of BCL2L14 gene expression have 
been reported for mucinous ovarian cancer relative 
to other histological subtypes of ovarian cancer 
(Heinzelmann-Schwarz et al., 2006). The functional 
significance of these changes are unknown. 
Subdivision of patients with high grade ovarian 
serous carcinoma into TP53 mutation-positive and 
p53 protein-null groups has revealed a number of 
differences in the genomic landscape, including 
gains of 12p13.2-12p13.1 (affecting DUSP16, 
BCL2L14 and ETV6) in the former group 
(Wojnarowicz et al., 2012). TP53 mutation-positive 
patients were also characterized by increased 
overall and disease-free survival (Wojnarowicz et 
al., 2012). 
Cervical cancer 
Note 
An integration site for HPV16 in cervical 
carcinoma has been mapped to BCL2L14 (Xu et al., 
2013). 
Lung cancer 
Note 
Analysis of variants in inflammation pathway genes 
has identified single nucleotide polymorphisms of 
BCL2L14 in former smokers that are associated 
with increased risk of developing lung cancer (Spitz 
et al., 2012). 
Precursor B acute lymphoblastic 
leukemia (ALL) 
Note 
A novel TEL-AML1 fusion transcript, comprising 
an in-frame insertion of 33 nucleotides derived 
from BCL2L14 between exon 5 of TEL and exon 2 
of AML1 has been described in a case of pediatric 
precursor B ALL (Abdelhaleem et al., 2006). This 
fusion transcript appears to be rare, and its 
biological effects are unknown. 
Tongue squamous cell carcinoma 
Note 
BCL2L14 expression has been reported to be 
markedly up-regulated in tongue squamous cell 
carcinoma tissue (Zhang et al., 2013). 
Systemic lupus erythematosus (SLE) 
Note 
BCL2L14 expression is up-regulated (ca. 8-fold) in 
CD4+ T-cells (but not CD8+ or B-cells) from 
patients with systemic lupus erythematosus (SLE) 
(Luo et al., 2009). In SLE, apoptosis is increased in 
CD4+ T-cells, and the degree of apoptosis in freshly 
isolated cells from SLE patients was directly 
correlated with Bcl-GL levels, as were other 
measures of disease activity status (Luo et al., 
2009). Healthy control CD4+ T-cells in vitro 
demonstrated enhanced apoptosis both after 
transfection with a lentiviral vector expressing 
BclGL and after treatment with serum from SLE 
patients; the latter effect was associated with 
increased BclGL cellular levels and could be 
partially inhibited by prior knockdown of BclGL 
(Luo et al., 2009). The serum factor(s) that mediate 
this response remain unknown; whilst interferon-α 
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was increased in SLE sera it alone could not 
account for enhanced Bcl-GL cellular levels (Luo et 
al., 2009). 
Innate immune response 
Note 
There are several reports of dysregulated expression 
of BCL2L14 in response to infection with a wide 
range of pathogens/parasites. For example, in 
Rhesus Macaque monkeys infected with 
Mycobacterium tuberculosis, BCL2L14 expression 
is initially enhanced in granulomas relative to 
normal lung tissue during the acute phase of disease 
but silenced several weeks post-infection (Mehra et 
al., 2010).  
While multiple markers of the pro-inflammatory 
response show a similar pattern, the silencing of 
BCL2L14 in chronic disease may contribute to 
pathogen survival. Studies with murine cells have 
further shown that exosomes derived from 
macrophages infected with Mycobacterium 
tuberculosis can block the activation of a subset of 
interferon-γ inducible genes, including BCL2L14, 
which may serve to suppress the host innate 
immune response beyond the site of infection 
(Singh et al., 2011).  
BCL2L14 is one of several Bcl-2 family members 
that is dysregulated in bovine endothelial cells 
following infection with the parasite Eimeria bovis 
(Taubert et al., 2010). It is markedly upregulated in 
human alveolar macrophages within a few hours of 
infection with H1N1 influenza A virus PR/8 (Wang 
et al., 2012) and it is also induced following the 
infection of human monocyte-derived dendritic 
cells with wild type Dengue 3 virus (a Flavivirus) 
or the chimeric CYD3 vaccine virus (Balas et al., 
2011). On the other hand, BCL2L14 expression is 
down-regulated in porcine epithelial cells following 
infection with Pseudorabies virus (a herpes virus) 
(Flori et al., 2008). 
BCL2L14 may also be implicated in the host 
response to viral evasion mechanisms per se. For 
example, selective expression of the African Swine 
Fever Virus evasion gene, A238L, in mouse T-
lymphocytes results in the production of an 
aggressive lymphoma (Almeida et al., 2012). 
Transgenic animals exhibit massively enlarged 
thymuses characterized, inter alia, by enhanced 
BCL2L14 expression and apoptosis (Almeida et al., 
2012).  
While attendant changes in host cell interferon 
signalling may account for many of the above 
changes in BCL2L14 expression, it should be noted 
that Bcl-G can directly interact with a component of 
the Flavivirus replication complex (Le Breton et al., 
2011).  
However, the biological significance of this 
interaction for both host and virus remains to be 
determined. The 3'-UTR of BCL2L14 transcripts 
also contains potential binding sites for Epstein-
Barr virus-derived miRNAs (Marquitz et al., 2011). 
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